Guiyang Xintian Pharmaceutical Co.,Ltd.
Shenzhen Stock ExchangeTotal Valuation
Guiyang Xintian Pharmaceutical Co.,Ltd. carries a market capitalization of 1.85B, placing it among publicly traded companies globally. Its enterprise value stands at 2.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.85B |
| Enterprise Value | 2.70B |
Share Statistics
Guiyang Xintian Pharmaceutical Co.,Ltd. currently has 244.10M shares outstanding.
| Shares Outstanding | 244.10M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Guiyang Xintian Pharmaceutical Co.,Ltd. trades at a trailing price-to-earnings ratio of 81.94. The price-to-sales ratio is 2.94, and the price-to-book ratio stands at 2.85.
| PE Ratio | 81.94 |
| PS Ratio | 2.94 |
| PB Ratio | 2.85 |
| P/TBV Ratio | 2.29 |
| P/FCF Ratio | 53.18 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Guiyang Xintian Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 87.15 and an EV/FCF ratio of 49.35. The EV/Sales ratio of 3.49 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 87.15 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.49 |
| EV / EBITDA | 87.15 |
| EV / EBIT | 87.15 |
| EV / FCF | 49.35 |
Financial Position
Guiyang Xintian Pharmaceutical Co.,Ltd. maintains a current ratio of 2.65, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.01, indicating elevated leverage, while an interest coverage ratio of 2.32 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.65 |
| Quick Ratio | 0.45 |
| Debt / Equity | 44.01 |
| Debt / EBITDA | 16.84 |
| Interest Coverage | 2.32 |
Financial Efficiency
Guiyang Xintian Pharmaceutical Co.,Ltd. posts a return on equity of 3.50 and a return on invested capital of 1.62.
| Return on Equity (ROE) | 3.50 |
| Return on Assets (ROA) | 1.47 |
| Return on Invested Capital (ROIC) | 1.62 |
| Return on Capital Employed (ROCE) | 2.83 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.40 |
Taxes
Over the trailing twelve months, Guiyang Xintian Pharmaceutical Co.,Ltd. has paid 3.21M in income taxes, reflecting an effective tax rate of 10.37.
| Income Tax | 3.21M |
| Effective Tax Rate | 10.37 |
Stock Price Statistics
Guiyang Xintian Pharmaceutical Co.,Ltd.'s stock has declined approximately -18.38006% over the past 52 weeks. The 50-day moving average sits at 8.83, while the 200-day moving average is 10.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -18.38006% |
| 50-Day Moving Average | 8.83 |
| 200-Day Moving Average | 10.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guiyang Xintian Pharmaceutical Co.,Ltd. generated 774.14M in revenue and converted that into 27.75M in net income, yielding earnings per share of 0.11. EBITDA reached 31.00M, while operating income came in at 31.00M.
| Revenue | 774.14M |
| Gross Profit | 556.23M |
| Operating Income | 31.00M |
| Pretax Income | 30.96M |
| Net Income | 27.75M |
| EBITDA | 31.00M |
| EBIT | 31.00M |
| Earnings Per Share (EPS) | 0.11 |
Balance Sheet
Guiyang Xintian Pharmaceutical Co.,Ltd. holds 94.56M in cash and equivalents against 522.09M in total debt, resulting in a net debt position of 409.55M. Total book value stands at 799.15M, with working capital of 348.83M providing operational flexibility.
| Cash & Cash Equivalents | 94.56M |
| Total Debt | 522.09M |
| Net Debt | 409.55M |
| Equity (Book Value) | 799.15M |
| Book Value Per Share | 3.28 |
| Working Capital | 348.83M |
Cash Flow
After subtracting -42.76M in capital expenditures, free cash flow totaled -42.76M - equivalent to -0.18 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -42.76M |
| Free Cash Flow | -42.76M |
| FCF Per Share | -0.18 |
Margins
Guiyang Xintian Pharmaceutical Co.,Ltd. operates with a gross margin of 71.85, reflecting its pricing power and cost economics. The operating margin of 4.00 and net profit margin of 3.58 provide insight into operational efficiency.
| Gross Margin | 71.85 |
| Operating Margin | 4.00 |
| Pretax Margin | 4.00 |
| Profit Margin | 3.58 |
| EBITDA Margin | 4.00 |
Dividends & Yields
The company's payout ratio of 154.82 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.18 |
| Dividend Yield | N/A |
| Payout Ratio | 154.82 |
| Shareholder Yield | 3.33 |
| FCF Yield | 1.88 |
Stock Splits
Guiyang Xintian Pharmaceutical Co.,Ltd.'s most recent stock split took place on October 28, 2022 with a 5:7 split ratio.
| Last Split Date | 10/28/2022 |
| Split Ratio | 5:7 |
Scores
Guiyang Xintian Pharmaceutical Co.,Ltd. posts an Altman Z-Score of 3.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.18 |